Deepak Garg. "Upfront low-dose diet-modified nilotinib versus standard imatinib in Indian patients with newly diagnosed chronic-phase chronic myeloid leukemia: The NILLOW phase II randomised trial.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.6584